AstraZeneca (AZN) and Daiichi Sankyo's Enhertu treatment showed a "statistically significant and clinically meaningful" improvement in overall survival, compared with ramucirumab plus paclitaxel in patients with second-line HER2 positive unresectable and/or metastatic gastric or gastroesophageal junction adenocarcinoma, Daiichi Sankyo said Saturday.
Based on the results from a phase 3 trial, Enhertu lowered the risk of death by 30% versus ramucirumab plus paclitaxel. Median overall survival was 14.7 months versus 11.4 months, according to the company.
In the secondary endpoint analysis of progression-free survival, Enhertu showed a 26% reduction in the risk of disease progression or death, compared with ramucirumab plus paclitaxel, Daiichi Sankyo said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.